About us
Osteoarthritis
Our solution
EU Consortium
Partners
News
English flag
Contact us
English flag
Osteoarthritis
Cross icon
About us
Osteoarthritis
Our solution
EU Consortium
Partners
News
Contact us
This image is illustrating osteoarthritis didease as the leading cause of disability in the world

The leading cause of disability in the world

Osteoarthritis (OA) is a serious disease, characterized by chronic joint pain and functional impairment.

Good to
‍know

OA is the leading cause of disability among people over 50.
More than 300 million people in the world have OA ≈ 15% of the adult population.
Walking impairment, limiting physical activity, increases mortality rate by 50% due to cardiovascular diseases onset.
Nearly one out of two adults will suffer from knee or hip OA in their lifetime.
≈ 600 Bn €/year in Europe total cost. A huge economic burden on patients and health care systems.
Prevalence is rising due to the aging population and epidemic of obesity worldwide.

What do we know about OA?

Figure illustrating the chronic joint disease called osteoarthritis
Made with

Osteoarthritis is a chronic joint disease characterized by structural deterioration of the whole joint.

The symptoms of this pathological condition are generally characterized by chronic pain associated with a functional impairment, i.e. stiffness and limitation of the joint mobility.

Figure illustrating the articular cartilage often damager by the disease called osteoarthritis
Made with

Articular cartilage is a connective tissue composed of chondrocytes and an extracellular matrix essentially formed from water, high molecular weight proteoglycans and type II collagen.

The good health of cartilage depends on continuous complex exchanges between chondrocytes and the matrix and is continually subjected to a balance between degradation (catabolism) and synthesis (anabolism).

Figure illustrating the destruction of articular cartilage as a result of chondrocyte failure cause of osteoarthritis disease
Made with

Destruction of articular cartilage is a result of chondrocyte failure to maintain balance between synthesis (anabolism) and degradation (catabolism) of cartilage matrix.

This imbalance essentially results in an increase of pro-degradative enzymes and a decrease of anabolic factors.

Moreover, proinflammatory cytokines, coming from the synovial tissue and produced by macrophages, monocytes, and synovial cells play an important role for the development of the disease.

Finding a
treatment for OA

Today, there is no available therapy that effectively alters the disease progression by stopping or even delaying joint structural damages while easing pain.

Current osteoarthritis treatments only focus on symptoms (pain and joint function). A recent review (Katz et al., JAMA, 2021) shows that just a few of these symptomatic treatments are strongly recommended by national and international medical organizations, the others being not, or only conditionally recommended mainly due to lack of efficacy and/or safety concerns.

As a last resort, surgical joint replacement, an invasive procedure, is proposed to patients with end-stage OA. Unfortunately, around 20% of patients with knee OA still experience chronic pain after surgery, highlighting the importance of finding new effective and long-acting disease-modifying treatments for OA patients.

Figure from Diagnosis and Treatment of Hip and Knee Osteoarthritis
Figure from Diagnosis and Treatment of Hip and Knee Osteoarthritis, Katz et al. Reproduced with permission from JAMA. 2021;325(6):568-578.
Copyright©(2021) American Medical Association. Allrights reserved.
Picture of Francis Berenbaum, Co-founder, Chief Executive Officer & Chief Medical Officer

“Today, there is a pressing need to bring curative treatment delaying the structural damage of the joints or restoring the cartilage. At 4Moving Biotech, our aim is to provide this long-term solution for patients through the development of 4P004, our disease-modifying treatment for OA (DMOAD).“

Prof. Francis Berenbaum, CEO/CMO of 4Moving Biotech, Head of rheumatology department at Saint-Antoine Hospital (AP-HP), Professor at Sorbonne University (Paris, France) and Director of a research team at INSERM CRSA.

Would you like to learn more about
our treatment 4P004?

Learn more about 4P004Learn more